We aim to use science for the benefit of human kind, and we aim for our science to have an impact. Our scientific discoveries build upon the work of previous great minds and the development of many molecular techniques, scientific methods, and technological breakthroughs, we have been able to contribute with novel insights within toxinology and antivenom development to the scientific community and society. With the support from generous donors, we have been able to make much of our work publicly available via publication in international peer-reviewed journals.

Peer review publications

Ledsgaard L, Kilstrup M, Karatt-Vellat A, McCafferty J, Laustsen AH. Basics of antibody phage display technology. Toxins 2018, 10 (6), 236
Laustsen AH. Toxin-centric development approach for next generation antivenoms. Toxicon 2018 150, p195-197
Laustsen AH, Gutiérrez JM, Knudsen C, Johansen KH, Bermúdez-Méndez E, Cerni FA, Jürgensen JA, Øhlenschlæger M, Ledsgaard L, Martos-Esteban A, Pus U, Andersen MR, Lomonte B, Engmark M, Pucca MB. Pros and cons of different therapeutic antibody formats for recombinant antivenom development. Toxicon 2018, 146; p151-175.
Engmark M, Jespersen MC, Lomonte B, Lund O, Laustsen AH. High-density peptide microarray exploration of the antibody response in a rabbit immunized with a neurotoxic venom fraction. Toxicon 2017, 138; p151-158.
Ainsworth S, Petras D, Engmark M, Süssmuth RD, Whiteley G, Albulescu LO, Kazandjian TD, Wagstaff SC, Rowley P, Wüster W, Dorrestein PC, Arias AS, Gutiérrez JM, Harrison RA, Casewell NR, Calvete JJ. The medical threat of mamba envenoming in sub-Saharan Africa revealed by genus-wide analysis of venom composition, toxicity and antivenomics profiling of available antivenoms. Journal of Proteomics 2017, 172; p173-189.
Laustsen AH. Guiding recombinant antivenom development by omics technologies. New Biotechnology 2017, in press.
Engmark M, Lomonte B, Gutiérrez JM, Laustsen AH, De Masi F, Andersen MR, Lund O. Cross-recognition of a pit viper (Crotalinae) polyspecific antivenom explored through high-density peptide microarray epitope mapping. PLoS Neglected Tropical Diseases 2017, 7; e0005768.
Laustsen AH, Johansen KH, Engmark M, Andersen MR. Recombinant snakebite antivenoms: A cost-competitive solution to a neglected tropical disease? PLoS Neglected Tropical Diseases 2017, 11; e0005361.
Laustsen AH, Engmark M, Clouser C, Timberlake S, Vigneault F, Gutiérrez JM, Lomonte B. Exploration of immunoglobulin transcriptomes from mice immunized with three­‐finger toxins and phospholipases A2 from the Central American coral snake, Micrurus nigrocinctus. PeerJ 2017, 5; e2924.
Laustsen AH, Lauridsen LP, Lomonte B, Andersen MR, Lohse B. Pitfalls to avoid when using phage display for snake toxins. Toxicon 2017, 126; p79-89.
Lauridsen LP, Laustsen AH, Lomonte B, Gutiérrez JM. Exploring the venom of the forest cobra snake: Toxicovenomics and antivenom profiling of Naja melanoleuca. Journal of Proteomics 2017, 150; p98-108.
Engmark M, Andersen MR, Laustsen AH, Patel J, Sullivan E, de Masi F, Hansen CS, Kringelum JV, Lomonte B, Gutiérrez JM, Lund O. High-throughput immuno-profiling of mamba (Dendroaspis) venom toxin epitopes using high-density peptide microarrays. Scientific Reports 2016, 6; 36629.
Laustsen AH. Costing recombinant antivenoms. Nature 2016, 538; p41
Laustsen AH. Toxin synergism in elapid snake venoms. Toxin Reviews 2016, 35; p165-170.
Laustsen AH, Solà M, Jappe EC, Oscoz S, Lauridsen LP, Engmark M. Biotechnological trends in spider and scorpion antivenom development. Toxins 2016, 8; p1-33
Laustsen AH. Recombinant antivenoms. PhD thesis. University of Copenhagen, Denmark. ISBN 978‐87­‐93086­‐61‐6.
Laustsen AH, Engmark M, Milbo C, Johannesen J, Lomonte B, Gutiérrez JM, and Lohse B. From Fangs to Pharmacology: The Future of Snakebite Envenoming Therapy. Current Pharmaceutical Design 2016, 22; p5270-5293.
Lauridsen LP, Laustsen AH, Lomonte B, Gutiérrez JM. Toxicovenomics and antivenom profiling of the Eastern green mamba snake (Dendroaspis angusticeps). Journal of Proteomics 2016, 136; p248-261.
Laustsen AH, Gutiérrez JM, Rasmussen AR, Engmark M, Gravlund P, Sanders KL, Lohse B, Lomonte B. Danger in the reef: Proteome, toxicity, and neutralization of the venom of the olive sea snake, Aipysurus laevis. Toxicon 2015, 107; p187-196.
Laustsen AH, Lohse B, Lomonte B, Engmark M, Gutiérrez JM. Selecting key toxins for focused development of elapid snake antivenoms and inhibitors guided by a Toxicity Score. Toxicon 2015, 104; p43-45.
Laustsen AH, Gutiérrez JM, Lohse B, Rasmussen AR, Fernández J, Milbo C, and Lomonte B. Snake venomics of monocled cobra (Naja kaouthia) and investigation of human IgG response against venom toxins. Toxicon 2015, 99; p23-35.
Laustsen AH, Lomonte B, Lohse B, Fernández J, Gutiérrez JM. Unveiling the nature of black mamba (Dendroaspis polylepis) venom through venomics and antivenom immunoprofiling: Identification of key toxin targets for antivenom development. Journal of Proteomics 2015, 119; p126-142.

Popular science publications

Føns S, Laustsen AH. Venoms that save lives. Splice 2018.
Fuglsang-Madsen A, Laustsen AH. Antistoffer kan designes i et reagensglas. Videnskab 2018.
Fuglsang-Madsen A, Laustsen AH. Antistoffer: Moderne lægemidler baseret på kroppens forsvarsmissiler. Videnskab 2018.
Laustsen AH, Jenkins TP. Big strides are being made in the push for affordable, effective antivenoms. The Conversation 2018.
Laustsen AH, Kiel CM. Slanger, der får dit blod til at stivne. Videnskab 2018.
Laustsen AH, Føns S. Gift redder menneskeliv. Videnskab 2018.
Laustsen AH, Povlsen H. Hvad sker der i kroppen, når man vaccineres mod HPV? Videnskab 2017.
(SPANISH) Bermúdez EM, Martos AE. Hacia una nueva generación de antivenenos contra las mordeduras de serpientes. DICYT 2017.
Laustsen AH, Pus U. Harnessing Biotechnology in the Fight Against Snakebite. Splice 2017.
Laustsen AH, Høgberg L. Snakebites still exact a high toll in Africa. A shortage of antivenoms is to blame. The Conversation 2017.
Laustsen AH, Jürgensen JA, Nielsen EP. Kan man dø af at spise slangegift? Videnskab 2017.
Laustsen AH, Øhlenschlæger M, Ledsgaard L. Hvorfor vaccinerer man ikke mod slangebid? Videnskab 2017.
Laustsen AH, Øhlenschlæger M, Knudsen C. Derfor har vi brug for moderne modgifte mod slangebid. Videnskab 2017.
Laustsen AH, Knudsen C, Øhlenschlæger M. Slangearters gift er unikke cocktails af dræberproteiner. Videnskab 2017.
Laustsen AH, Engmark M. How biotechnology could offer hope for snakebite victims. The Conversation 2016.


Large grants
Hørslev Fonden

2017 · DKK 150,000

Novo Nordisk Foundation

2016 · DKK 1,695,876

2013 · DKK 2,100,000

Small grants
Symphogen A/S
Otto Mønsteds Fond
Knud Højgaards Fond
Oticon Fonden